Biotech News

MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance

MaxCyte (MXCT)MaxCyteEarnings

MaxCyte will host its third quarter 2026 earnings call today, November 10th, at 8:30 a.m. Eastern Time Third Quarter and Recent Business Highlights: Reports total revenue of $10.2 million for the third quarter of 2026, including $8.2 million of core revenue and $2.0 million of SPL Program-related

Related news

MaxCyte

Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...

Recent company news

Stock data

Close
1.28 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States